Modified fusion proteins of transferrin and therapeutic proteins or peptides including soluble toxin receptors, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.
申请公布号
WO2004020405(A2)
申请公布日期
2004.03.11
申请号
WO2003US26818
申请日期
2003.08.28
申请人
BIOREXIS PHARMACEUTICAL CORPORATION;PRIOR, CHRISTOPHER, P.;LAI, CHAR-HUEI;SADEGHI, HOMAYOUN;TURNER, ANDREW, J.
发明人
PRIOR, CHRISTOPHER, P.;LAI, CHAR-HUEI;SADEGHI, HOMAYOUN;TURNER, ANDREW, J.